Abstract
Continuous glucose monitoring (CGM) is developing into an increasingly useful tool for glucose monitoring and therapeutic guidance in the treatment of diabetes. Multiple daily doses of insulin (MDI) is the most common method for intensive insulin treatment of type 1 diabetes and is also becoming more common in the treatment of type 2 diabetes as an increasing population with type 2 diabetes experiences progressive beta cell loss. The clinical evidence demonstrating the benefit of CGM in the outcomes of patients treated with MDI is becoming clearer, particularly with the recent completion of several randomized clinical trials addressing both type 1 and 2 diabetes. This evidence is reviewed.
Original language | English (US) |
---|---|
Pages (from-to) | S3-S12 |
Journal | Diabetes Technology and Therapeutics |
Volume | 19 |
DOIs | |
State | Published - Jun 2017 |
Keywords
- Continuous glucose monitoring
- Diamond Study
- Hypoglycemia
- Multiple daily doses of insulin
- Type 1 diabetes
- Type 2 diabetes
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Endocrinology
- Medical Laboratory Technology